Profile data is unavailable for this security.
About the company
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
- Revenue in USD (TTM)134.48m
- Net income in USD-63.43m
- Incorporated2022
- Employees263.00
- LocationZymeworks Inc108 Patriot Drive, Suite AMIDDLETOWN 19709United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.zymeworks.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -15.84m | 1.69bn | 5.00 | -- | 5.59 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.71bn | 65.00 | -- | 3.58 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Pharvaris NV | 0.00 | -190.13m | 1.72bn | 108.00 | -- | 4.80 | -- | -- | -3.39 | -3.39 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.76bn | 192.00 | -- | 3.02 | -- | 114.64 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.76bn | 60.00 | -- | 6.27 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Definium Therapeutics Inc | 0.00 | -183.79m | 1.76bn | 105.00 | -- | 5.26 | -- | -- | -2.06 | -2.06 | 0.00 | 3.36 | 0.00 | -- | -- | 0.00 | -49.52 | -52.67 | -57.73 | -60.64 | -- | -- | -- | -- | -- | -- | 0.1088 | -- | -- | -- | -69.12 | -- | -- | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.83bn | 263.00 | -- | 5.78 | -- | 13.61 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.84bn | 122.00 | -- | 5.23 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.86bn | 61.00 | -- | 15.73 | -- | 29.69 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Recursion Pharmaceuticals Inc | 74.68m | -644.76m | 1.87bn | 600.00 | -- | 1.65 | -- | 25.00 | -1.48 | -1.48 | 0.167 | 2.14 | 0.0511 | -- | 2.02 | 124,468.30 | -44.12 | -43.31 | -49.84 | -49.18 | 4.99 | -- | -863.35 | -816.44 | -- | -- | 0.0162 | -- | 26.92 | 79.91 | -39.06 | -- | 2.10 | -- |
| Syndax Pharmaceuticals Inc | 172.60m | -285.42m | 1.89bn | 298.00 | -- | 28.94 | -- | 10.94 | -3.30 | -3.30 | 2.00 | 0.7394 | 0.2752 | 0.4209 | 7.57 | 579,191.30 | -45.50 | -34.74 | -55.38 | -38.78 | 95.96 | -- | -165.37 | -279.37 | 4.12 | -24.68 | 0.8418 | -- | 627.84 | 157.68 | 10.46 | -- | -- | -- |
| Celldex Therapeutics Inc | 1.55m | -258.76m | 1.93bn | 198.00 | -- | 3.65 | -- | 1,246.07 | -3.90 | -3.90 | 0.0233 | 7.92 | 0.0023 | -- | 1.14 | 7,808.08 | -37.63 | -30.06 | -40.28 | -31.85 | -- | -- | -16,737.19 | -3,299.27 | -- | -- | 0.00 | -- | -77.99 | -26.93 | -63.91 | -- | 11.83 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.93bn | 128.00 | 51.18 | 6.04 | 45.44 | 9.38 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Soleno Therapeutics Inc | 190.41m | 20.48m | 1.95bn | 182.00 | 244.03 | 4.38 | 85.01 | 10.23 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Zymeworks Inc's reporting currency: US Dollar USD
66.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Dec 2025 | 22.97m | 30.69% |
| Rubric Capital Management LPas of 31 Dec 2025 | 5.75m | 7.68% |
| BVF Partners LPas of 31 Dec 2025 | 3.94m | 5.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.44m | 4.60% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 3.26m | 4.36% |
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 2.53m | 3.38% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.52m | 3.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.20m | 2.95% |
| BNP Paribas Asset Management USA, Inc.as of 31 Dec 2025 | 1.66m | 2.22% |
| DWS Investments (UK) Ltd.as of 31 Dec 2025 | 1.45m | 1.93% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
